Sign In
Buy TEVA
$32.83
-0.250 (-0.756%)
At Close: Jun 03, 2026
Teva and Medincell's schizophrenia drug meets main goal of late-stage study
06:41am, Wednesday, 08'th May 2024
Teva Pharmaceuticals , and partner Medincell said on Wednesday their experimental schizophrenia drug had met its main goal in a late-stage study.
PARSIPPANY, N.J. & TEL AVIV & PARIS--(BUSINESS WIRE)--ACCESS HERE THE COMPLETE PRESS RELEASE Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Me
Teva Earnings Are Coming. What Could Keep the Stock Gains Going.
04:30pm, Tuesday, 07'th May 2024
The pharmaceutical company reports before the market open Wednesday.
Watch These 5 Drug Stocks for Q1 Earnings: Beat or Miss?
11:41am, Monday, 06'th May 2024
Let us look at five drug, generic companies, PRGO, IOVA, VTRS, TEVA and ACAD, which are gearing up for their earnings release this week.
Unlocking Q1 Potential of Teva Pharmaceutical Industries (TEVA): Exploring Wall Street Estimates for Key Metrics
10:21am, Friday, 03'rd May 2024
Evaluate the expected performance of Teva Pharmaceutical Industries (TEVA) for the quarter ended March 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining som
Teva to Present at the 2024 Bank of America Healthcare Conference
06:30pm, Thursday, 02'nd May 2024
TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at the 2024 Bank of America He
Teva's 2023 Healthy Future Report Showcases Renewed Sustainability Strategy and Ambitious Targets
08:30am, Thursday, 02'nd May 2024
TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today published its 2023 Healthy Future Report, sharing its actions to promote healthy people, a healthy pl
FTC Warns ‘Junk Patents' Could Make Drugs Like Ozempic Pricier—Here's How
01:56pm, Tuesday, 30'th Apr 2024
The Federal Trade Commission is challenging hundreds of alleged “junk” patent listings filed by several pharmaceutical companies, which regulators claim could increase prices for medications like
You Would Fire “God” As Your Portfolio Manager
04:44pm, Tuesday, 23'rd Apr 2024
Investors are growing nervous
3 Generic Drug Stocks to Watch Amid Challenging Market Prospects
12:16pm, Thursday, 18'th Apr 2024
The impact of macroeconomic headwinds on the Zacks Medical - Generic Drugs industry is gradually improving. New product launches provide some respite to RDY, TEVA and VTRS.
Teva to Host Conference Call to Discuss First Quarter 2024 Financial Results at 8 a.m. ET on May 8, 2024
04:30pm, Tuesday, 09'th Apr 2024
TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its first quarter 2024 financial results on Wednesday
Teva, Viatris win new chance to challenge J&J schizophrenia drug patent
11:53am, Monday, 01'st Apr 2024
Teva Pharmaceutical and Viatris convinced a U.S. appeals court on Monday to revive their challenges to a patent covering a blockbuster Johnson & Johnson schizophrenia drug, giving them a new chance to
6 reasons to buy Teva Pharmaceuticals stock sooner than later
06:21am, Monday, 26'th Feb 2024
Teva Pharmaceutical Industries Ltd. NYSE: TEVA is a global pharmaceutical company in the medical sector specializing in generic and specialty medications.
Teva Pharm to stay as unified generics, branded drugmaker, CEO says
04:45am, Tuesday, 20'th Feb 2024
Teva Pharmaceutical Industries will remain a single company for both generic and branded drugs since generics help to fund research and development of its innovative medicines, Chief Executive Richard
TEVA Q4 Earnings and Revenues Surpass Estimates, Stock Up
12:56pm, Thursday, 01'st Feb 2024
TEVA reports better-than-expected fourth-quarter results, beating both earnings and sales estimates. The stock gains 3% in response.
